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Purpose: To evaluate the pharmacokinetics of the major compounds in Ginkgo leaf dosage 
formulations (namely, Yikangning tablets, Ginaton tablets, Aoshi dropping pills and Yinxinke dispersible 
tablets), commonly used in traditional Chinese medicine. 
Methods: A randomized 4*4 crossover study with eight beagle dogs was carried out. Plasma samples 
were collected following oral administration of four different preparations and the effective ingredients, 
namely, kaempferol, quercetin, isorhamnetin, ginkgolides A, ginkgolides B, ginkgolides C and bilobalide 
were detected by a validated ultra-performance liquid chromatography-tandem mass spectrometry 
(UPLC-TMS). Then the pharmacokinetics of these target compounds, of different preparations were 
studied. 
Results: The adjusted pharmacokinetic data showed that the area under the concentration-time curve 
from time-zero to the last measurable concentration (AUC0-t) of kaempferol, quercetin, isorhamnetin, 
bilobalide, ginkgolides A, ginkgolides B, and ginkgolides C in plasma ranged from 124.37 ± 90.46 to 
2261.87 ± 812.35, after administration of Yikangning; 142.28 ± 62.37 to 2529.46 ± 320.48 µg/L•h 
following administration of Ginaton; 158.52 ± 55.48 to 1987.40 ± 766.21 µg/L•h after Aoshi 
administration; 160.49 ± 104.66 to 2016.92 ± 1150.92 µg/L•h following Yinxinke administration. The 
results also indicate that the flavonoids (especially quercetin) in dispersible tablets and dropping pills 
hexhibited higher AUC than those in conventional tablets. There were no differences between Aoshi 
(dropping pills) and Yinxinke (dispersible tablets) in terms of the bioavailability of the flavonoids, but the 
dropping pill flavonoids showed lower tmax. 
Conclusion: The results indicate that UPLC-TMS can used to simultaneously evaluate the plasma 
pharmacokinetics of Ginko compounds in beagle dogs 
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Ginkgo probably originated thousands of years 
ago. Ginkgo biloba leaf extracts (GBE) contain 
72 ginkgo constituents, including terpene 
lactones, flavonols, flavones, isoflavones, 
biflavones, flavanols, and carboxylic acids. The 
pharmacological activities of GBE are attributed 
to the synergistic action of terpene lactones and 
flavonoid glycosides. The products of GBE have 
become widely used as botanical medicines and 
dietary supplements, especially for  the 
prevention and treatment of cardiovascular 
diseases [1] and cerebral insufficiency [2-6]. 
 
One of the challenges in clinical application of 
GBE preparations is the low bioavailability [7] (10 
%), poor solubility, poor permeability [8] and the 
physical problem of delivering a drug across the 
blood–brain barrier. Hence, many new 
formulations emerged in the recent years, such 
as, phospholipid, complexes, tablets [9], solid 
dispersions [10], and dropping pills. Each 
formulation has both advantages and 
disadvantages. For conventional tablets, their 
technology is sample and auto-operation but they 
are really hard to take for people who have 
difficulty swallowing. 
 
Solid dispersible tablets can disintegrate and 
disperse quickly in the water and in mouth. They 
have the features of fast acting and high 
pharmacological effect. However, the solid 
dispersible tablets must add amount of 
disintegrants and use micronized raw medicinal 
material. Dropping pills are prepared by the solid 
dispersion technology. The process has the 
advantages of simple equipment, easy control, 
high efficiency and low cost. However, dropping 
pills have poor drug loading. 
 
Are new preparations better than conventional 
tablets in clinical practice? So far, many studies 
were carried out on preparation methods and in 
vitro dissolution of new preparations, but few in 
vivo studies have been done. According to the 
Food and Drug Administration of the United 
States, botanical drug products should be 
investigated with regard to blood levels of known 
representative markers, active constituents, 
and/or major chemical constituents. However, so 
far, the pharmacokinetic studies of GBE have 
been carried on mostly in rats, and were deficient 
in comparisons of different preparations [11-14]. 
 
The aim of this study was to evaluate the the 
pharmacokinetic profiles of four different GBE 
formulations   -   Yikangning   tablets,   Ginaton 
tablets, Aoshi dropping pills, and Yinxinke 
dispersible tablets - after a single oral 
administration in beagle dogs, using a previously 
developed ultrahigh-performance liquid 
chromatography coupled with triple quadrupole 
mass (UPLC–MS/MS) to quantify kaempferol 
(KMF), quercetin (QCT), isorhamnetin (ISR), 
ginkgolides A (GA), ginkgolides B (GB), 





Chemicals and Ginkgo leaf preparations 
 
The standards of kaempferol (KMF), quercetin 
(QCT), isorhamnetin (ISR), ginkgolides A (GA), 
ginkgolides B (GB), ginkgolides C (GC) and 
bilobalide (BB) and domperidone (DPD) (IS) 
were purchased from the National Institute for 
the Control of Pharmaceutical and Biological 
Products (Beijing, China). The purity of QCT and 
GC was 96.5 and 97.1 %, respectively. The 
purity of the remaining standards was more than 
99 %. LC/MS grades of methanol and acetonitrile 
were obtained from Fisher Scientific (Fair Lawn, 
NJ, USA), HPLC grade of formic acid was 
supplied by ROE Scientific (Newcastle,  USA), 
and ultrapure water was generated from the 
Synergy UV water purification system (Millipore 
Corp, USA). 
 
Yikangning tablets of G. biloba leaves extract 
were made by Yangtze River Pharmaceutical 
Group Co. Ltd Jiangsu, China. Each tablet 
contained 80 mg of the extracts. (Batch: 
12062621). Ginaton tablets of G. biloba leaves 
extract were made by Willmar Schwabe GmbH & 
Co. KG (Germany). Each tablet contained 40 mg 
of the extract. (Batch no. 1941211). Aoshi 
dropping pills of G. biloba leaves extract were 
made by Zhejiang Jiuxu Pharmaceutical Co., Ltd 
Zhejiang, China. Each pill contained 10 mg of the 
extract (Batch no. 20120709). Yinxinke 
dispersible tablets of G. biloba leaves extract 
were made by Jiangsu Shenlong Pharmaceutical 
Co., Ltd. (Jiangsu, China). Each tablet contained 
40 mg ginkgo extractum (Batch no. 120702). 
 
Instrumentation and chromatographic 
conditions 
 
The UPLC–MS/MS system used was composed 
of an Acquity UPLC system and a TQS triple 
quadrupole tandem mass spectrometer. 
Chromatographic separation was performed on 
an ACQUITY UPLC BEH C18 column. The 
column temperature was maintained at 40  °C 
and the auto-sampler was conditioned at 4 °C. 
The mobile phase was composed of 0.1 % formic 
Trop J Pharm Res, May 2015; 14(5): 881 




acid aqueous solution (A) and acetonitrile (B) at 
a flow rate of 0.4 mL/min in only 4.0 minutes. 
Gradient condition of the mobile phase was as 
follows: 5 % B at 0–1.0 min; 5 → 40 % B at 1.0– 
1.5 min; 40 % → 43 % B at 1.5–3.0 min, then the 
system was equilibrated using the initial condition 
(acetonitrile–water, 5:95, v/v) for 1.0 min. 
 
Assay of the preparations 
 
The four ginkgo leaf preparations (GLP) were 
analyzed by UPLC–MS/MS. The method can be 
applied to simultaneous determination of KMF, 
QCT, ISR, BB, GA, GB and GC. Table 1 shows 
the levels of KMF, QCT, ISR, BB, GA, GB and 
GC in the four GLP. Acid hydrolysis was applied 
to convert flavonoid glycosides into their 
aglycone forms before measuring the contents of 




This study complied with the Guiding Principles 
for the Care and Use of Laboratory Animal and 
was approved by the Institutional Animal Care 
and Use Committee of the Beijing University of 
Chinese Medicine (SPF animal, certificate no. 
SCXK (Jing) 2013-0007). 
 
Eight male beagle dogs weighing 11.1 ± 0.3 kg 
were used. The dogs were housed in a stainless 
steel cage, with an ambient temperature of 21 – 
22 °C and unlimited access to standard 
laboratory dog diet and water. Except for ad 
libitum water, the animals were fasted for 12 h 
prior to drug administration. 
 
Then a randomized 4*4 crossover trial with eight 
beagle dogs was carried out to study the 
pharmacokinetic characteristics. In the  design, 
the equal numbers of subjects are initially 
assigned to each sequence. Each subject was 
randomly assigned to any sequence. The 
advantage of the randomized 4*4 crossover 
study is to reduce the number of animals and 
improve the data reliability by eliminating the 
error from the experimental period and animals 
individuals. The design is presented in Table 2. 
 
Eight male beagle dogs were divided randomly 
into four groups, and each group was treated 
with a single dose of Yikangning, Ginaton, Aoshi 
and Yinxinke (take Ginaton as the reference 
preparation). Each dog received an oral dose 
equivalent to 640 mg extract under fasting 
conditions, that is, 8 tablets of Yikangning, 16 
tablets of Ginaton, 64 pills of Aoshi, and 16 
tablets of Yinxinke. Drugs were put into the 
epiglottis of beagle dogs, and then the dogs were 
made to automatically swallow and drink 50 mL 
water. There was a washout period of 2 weeks 
between the two adjacent periods, and the order 
of the drug administration was randomized. 
 
Blood samples were collected for up to 48 h (at 
0, 10, 20, 30 and 45 min, then 1, 1.5, 2, 3, 4, 5, 
6, 8, 10, 12, 24, 36, and 48 h after 
administration). The blood samples were 
centrifuged at 5000 rpm for 10 min; then the 
supernatant plasma were collected into tightly 
sealed plastic tubes (containing heparin sodium 
anticoagulant solution), and were finally frozen at 
- 20 °C until used for analysis. 
 
All the plasma samples were extracted by using 
liquid–liquid extraction technique as was 
described. Hydrochloric acid was added into the 
samples to convert flavonoid glycosides into their 
aglycone forms. Accordingly, the measured 
flavonoid levels were expressed as the 
concentrations of KMF, QCT and ISR. The 
samples were prepared as following steps: The 
plasma sample was hydrolyzed for 30 min in a 
 















Table 2: A four-period crossover design for drug administration 
 
Period Sequence A Sequence B Sequence C Sequence D 
1 Yinxinke Reference Yikangning Aoshi 
2 Reference Yinxinke Aoshi Yikangning 
3 Yikangning Aoshi Reference Yinxinke 









3.95 1.36 0.51 3.49 
3.39 1.36 0.45 2.79 
1.59 0.38 0.24 1.25 
3.25 1.30 0.47 2.81 
1.45 0.34 0.22 1.05 
1.03 0.30 0.19 0.70 
1.01 0.33 0.08 0.59 
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water bath at 80 °C and extracted with acetidin 




The pharmacokinetic parameters of different 
preparations are comparable only if the dogs are 
treated with the same dosage, but the drug 
contents (7 effective ingredients) of these 
preparations were not the same, so a dosage 
conversion factor was calculated as in Eq 1. 
 
i = Dr/Dt = (nrmr)/(ntmt)…………………… (1) 
 
where i is the conversion factor, Dr (mg) is the 
administration dosage of reference preparation, 
Dt (mg) is the administration dosage of test 
preparation, nr (tablet or pill) is the number of 
reference preparation, mr (mg/ tablet or mg/ pill) 
is the content of reference preparation, nt (tablet 
or pill) is the number of test preparation, and mt 
(mg/ tablet or mg/ pill) is the content of test 
preparation. 
 
Second, the conversion factor was multiplied by 
the measured plasma concentration of QCT, 
KMF, ISR, BB, GA, GB, and GC to calculate the 
corresponding plasma concentrations when the 
dogs are treated with the same dose. 
 
The pharmacokinetic parameters, AUC0-t and 
T1/2, were calculated with the software program 
DAS 3.20 (non-compartmental model). Cmax 
and Tmax were the actual values. Data were 
analyzed using SPSS 17.0. AUC0-t and Cmax 
were compared via analysis  of  variance 
(ANOVA)   and   multiple   comparisons   (least 
significance difference, LSD).  Tmax  was 
measured using nonparametric statistical tests 
(Wilcoxon). 
 
The relative bioavailability (Fr) was calculated as 
in Eq 2, using Ginaton as the reference 
preparation. 
 
Fr = AUCt/AUCr……………………………… (2) 
 
where AUCr (µg/L•h) is the area under the 
concentration–time curve of the reference 
preparation and AUCt (µg/L•h) is the area under 





The calculation formulas for the total flavone 
glycol glycosides and the total  lactones 
according to Chinese Pharmacopoeia (2010 
version) and USP 35 – NF 30 are as follows: (1) 
total flavone glycol glycosides (total flavonoids) = 
2.51（KMF + QCT + ISR）and (2) total lactones 
= BB + GA + GB + GC. Figs 1 - 9 show the mean 
plasma concentration–time curves of the seven 
sample total flavonoids, and total terpene 
lactones in beagle dog plasma after 
administration of four different GLP. Plasma 
concentration–time data derived from the 
experiments were analyzed by DAS 3.20 (non- 
compartmental model), and the main 




Fig 1: Concentration-time curve of kaempferol (KMF) for different preparations 
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Fig 3: Concentration-time curve of isorhamnetin (ISR) for different preparations 
Lu et al 















Fig 5: Concentration-time curve of bilobalide (BB) for different preparations 
Lu et al 
















Fig 7: Concentration-time curve of ginkgolides B (GB) for different preparations 
Lu et al 













Fig 9: Concentration-time curve of total terpene lactones for different preparations 
Lu et al 




Table 3: Major pharmacokinetic parameters (non-compartmental model) and relative bioavailability of flavonoids 































Yikangning 21.76±7.94 1.63±0.64 26.97±17.15 215.38±126.37 97.15 
Ginaton 17.02±7.91 1.63±1.12 14.42±4.96 221.70±80.48 100.00 
Aoshi 11.68±4.57 0.72±0.21 18.15±12.68 267.84±88.99 120.81 
Yinxinke 13.28±7.74 1.34±0.48 23.52±9.10 221.25±95.03 99.80 
Yikangning 14.60±7.99 1.53±0.71 22.97±14.50 151.60±124.33 93.13 
Ginaton 9.82 ±3.61 1.83±1.43 14.22±6.73 162.78±111.66 100.00 
Aoshi 5.24 ±2.31 0.75±0.35 22.49±14.17 275.85±158.87 169.46 
Yinxinke 12.07±6.75 1.34±0.40 45.31±25.47 305.46±178.81 187.65 
Yikangning 10.60±3.91 2.06±1.35 12.54±8.31 124.37±90.46 87.41 
Ginaton 10.97±5.07 2.04±1.25 15.75±12.06 142.28±62.37 100.00 
Aoshi 6.13 ±3.33 0.75±0.19 6.53±4.66 218.57±119.21 153.62 
Yinxinke 8.67 ±3.24 2.22±1.76 11.66±5.64 182.00±160.10 127.92 
Yikangning 13.20±5.69 1.50±0.76 157.54±98.62 1235.01±864.17 96.53 
Ginaton 10.29±2.90 1.17±1.12 118.31±72.48 1279.36±644.11 100.00 
Aoshi 8.58 ±2.96 0.69±0.22 114.18±72.48 1987.13±937.30 155.32 
Yinxinke 16.73±9.83 1.34±0.40 197.87±92.27 1785.00±1063.65 139.52 
Table 4: The main pharmacokinetic parameters (no compartmental) and the relative bioavailability of lactones 

































Yikangning 3.43 ±1.54 1.88 ±0.52 517.15±202.96 2261.87±812.35 89.42 
Ginaton 2.02 ±0.51 1.67 ±0.75 697.56±224.22 2529.46±320.48 100.00 
Aoshi 2.35 ±0.76 1.44 ±0.42 464.99±241.46 1987.40±766.21 78.57 
Yinxinke 3.54 ±2.04 1.75 ±0.60 380.23±176.66 2016.92±1150.92 79.74 
Yikangning 1.60± 1.07 1.50±0.66 185.19±60.37 486.53±120.21 116.08 
Ginaton 1.07±0.45 1.08±0.47 170.44±40.07 419.12±96.72 100.00 
Aoshi 2.19±1.75 1.00±0.33 88.52±48.80 198.65±80.78 47.40 
Yinxinke 1.68±1.26 1.03±0.51 78.96±61.15 271.68±248.38 64.82 
Yikangning 1.51± 1.03 1.41 ±0.71 60.31±33.31 186.37±154.12 111.33 
Ginaton 2.14 ±1.24 1.29 ±0.46 57.80±28.23 167.40±96.39 100.00 
Aoshi 2.41 ±1.21 1.06 ±0.29 34.85±19.27 76.61±33.73 45.76 
Yinxinke 2.21 ±1.47 1.22 ±0.41 69.98±35.10 245.23±160.49 146.49 
Yikangning 7.97±4.04 2.13±0.35 32.21±11.19 291.73±184.40 137.56 
Ginaton 5.50±2.82 2.17±0.68 36.65±15.03 212.07±124.85 100.00 
Aoshi 5.55±2.19 1.81±0.65 18.14±8.33 158.52±55.48 74.75 
Yinxinke 5.08±2.82 2.06±0.42 25.94±10.15 160.49±104.66 75.68 
Yikangning 7.51 ±4.66 1.63 ±0.58 743.4±212.79 3007.64±901.24 88.36 
Ginaton 3.47 ±2.47 1.42 ±0.38 926.71±198.67 3403.77±295.20 100.00 
Aoshi 3.45 ±1.28 1.34 ±0.48 535.87±260.73 2293.22±767.82 67.37 
Yinxinke 3.82 ±1.95 1.50 ±0.76 520.46±205.27 2572.24±1453.58 75.57 
To analyze AUC0-t, Cmax, and Tmax of flavonoids in 
the four different GLP with the LSD pairwise 
comparison methods, which reveal that, for KMF, 
there was no significant difference for AUC0-t of 
the four different GLP. For QCT, AUC0-t and Cmax 
of Yinxinke had a significant difference compared 
with Yikangning or Ginaton (p < 0.05); for ISR 
and total flavonoids, there were no significant 
differences for AUC0-t and Cmax of the four 
different GLP. The conclusion suggests that 
dispersible tablets can increase QCT absorption 
and bioavailability of QCT in vivo compared with 
traditional tablets. Besides, the Tmax of dropping 
pill Aoshi was found to be significantly lower 
among the four preparations. 
To analyze AUC0-t, Cmax, and Tmax of lactones in 
the four different GLP with the LSD pairwise 
comparison methods, which indicate that, for BB, 
there were no significant differences for AUC0-t of 
the four different GLP, but Ginaton had a higher 
Cmax compared with solid dispersions (Aoshi) and 
dispersible tablet (Yinxinke, p < 0.05). For GA, 
there were higher AUC0-t and Cmax when 
Yikangning and Ginaton were compared with 
Aoshi and Yinxinke (p < 0.05). For GB, Aoshi 
had lower AUC0-t and Cmax, when compared with 
Yikangning and Yinxingke (p < 0.05), the Cmax of 
Aoshi was also lower than them. For GC, there 
were higher AUC0-t  and Cmax  when Yikangning 
Lu et al 




was compared with Aoshi (p < 0.05); the Cmax of 
Ginaton was also higher than Aoshi and 
Yinxingke (p < 0.05). For total lactones, Ginaton 
had higher AUC0-t and Cmax, when compared with 




In this study, a four-period crossover trial was 
used in pharmacokinetic studies. The crossover 
design eliminates variability caused by subject 
(dog) differences in drug absorption, drug 
clearance, and the volume of drug distribution. 
 
The plasma concentration–time curves of QCT, 
KMF, and ISR and total flavonoids in beagle dog 
plasma after administration of the four different 
GLP show double peaks. The findings are 
consistent with previously reports. Some 
researchers [15,16] considered that it might be 
caused by some factors, such as enterohepatic 
circulation [7,17], distribution of the drug in vivo, 
and so on. To clarity the reason of double peaks 
of QCT, KMF, and ISR, a study on the absorption 
mechanism was performed [15]. The results 
demonstrated that the first peaks were produced 
by absorption–conjugation of the GBE-containing 
aglycones in the small intestine, and the second 
peaks were produced by the colonic 
deglycosylation–absorption–conjugation of the 
unabsorbed flavonoid glycosides. 
 
In this study, the measured plasma 
concentrations of QCT, KMF, ISR, BB, GA, GB, 
and GC were multiplied by a conversion factor to 
calculate the corresponding plasma 
concentrations of each compound under the 
same dose. The results suggest that dispersible 
tablets and dropping pills can increase 
absorption and bioavailability of flavonoids 
(especially for QCT) in vivo compared with 
conventional tablet, and this has adverse 
consequences for lactones. Studies show that 
the lactones are unstable under acidic 
conditions, and therefore, preparations with good 
disintegrating property may cause greater 




Among these preparations, Yinxinke, a 
dispersible tablet improved the AUC0-t and Cmax 
of quercetin, while Aoshi, the dropping pill 
shortened the Tmax of  all the flavonoids. Good 
disintegrating property is helpful to the absorption 
of flavonoids, but may be disadvantageous for 
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